Selected research
Industry Research
Tofacitinib Citrate Extended-Release Tablets Industry Research Report 2026
Market perspective
The global Tofacitinib Citrate Extended-Release Tablets market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Tofacitinib Citrate Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Tofacitinib Citrate Extended-Release Tablets is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Tofacitinib Citrate Extended-Release Tablets is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Tofacitinib Citrate Extended-Release Tablets include Yichang Humanwell Pharmaceutical, Sichuan Kelun Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lepu Pharmaceutical, Sino Therapeutics, Zydus and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Tofacitinib Citrate Extended-Release Tablets market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tofacitinib Citrate Extended-Release Tablets Market by Company
Yichang Humanwell Pharmaceutical
Sichuan Kelun Pharmaceutical
CSPC Ouyi Pharmaceutical
Qilu Pharmaceutical
Lepu Pharmaceutical
Sino Therapeutics
Zydus
Pfizer
Tofacitinib Citrate Extended-Release Tablets Segment by Type
11mg per Tablet
22mg per Tablet
Tofacitinib Citrate Extended-Release Tablets Segment by Application
Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Ulcerative Colitis
Other
Tofacitinib Citrate Extended-Release Tablets Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tofacitinib Citrate Extended-Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tofacitinib Citrate Extended-Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tofacitinib Citrate Extended-Release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Tofacitinib Citrate Extended-Release Tablets manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Tofacitinib Citrate Extended-Release Tablets by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Tofacitinib Citrate Extended-Release Tablets in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 11mg per Tablet
- 22mg per Tablet
Applications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Ulcerative Colitis
- Other
Companies covered
- Yichang Humanwell Pharmaceutical
- Sichuan Kelun Pharmaceutical
- CSPC Ouyi Pharmaceutical
- Qilu Pharmaceutical
- Lepu Pharmaceutical
- Sino Therapeutics
- Zydus
- Pfizer
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Tofacitinib Citrate Extended-Release Tablets Market Size (2021-2032)
- 2.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales (2021-2032)
- 2.2.3 Global Tofacitinib Citrate Extended-Release Tablets Market Average Price (2021-2032)
- 2.3 Tofacitinib Citrate Extended-Release Tablets by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 11mg per Tablet
- 2.3.3 22mg per Tablet
- 2.4 Tofacitinib Citrate Extended-Release Tablets by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Rheumatoid Arthritis
- 2.4.3 Psoriatic Arthritis
- 2.4.4 Ankylosing Spondylitis
- 2.4.5 Ulcerative Colitis
- 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Tofacitinib Citrate Extended-Release Tablets Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tofacitinib Citrate Extended-Release Tablets Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue of Manufacturers (2021-2026)
- 3.4 Global Tofacitinib Citrate Extended-Release Tablets Average Price by Manufacturers (2021-2026)
- 3.5 Global Tofacitinib Citrate Extended-Release Tablets Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Product Type & Application
- 3.8 Global Manufacturers of Tofacitinib Citrate Extended-Release Tablets, Established Date
- 3.9 Global Tofacitinib Citrate Extended-Release Tablets Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yichang Humanwell Pharmaceutical
- 4.1.1 Yichang Humanwell Pharmaceutical Company Information
- 4.1.2 Yichang Humanwell Pharmaceutical Business Overview
- 4.1.3 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- 4.1.5 Yichang Humanwell Pharmaceutical Recent Developments
- 4.2 Sichuan Kelun Pharmaceutical
- 4.2.1 Sichuan Kelun Pharmaceutical Company Information
- 4.2.2 Sichuan Kelun Pharmaceutical Business Overview
- 4.2.3 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- 4.2.5 Sichuan Kelun Pharmaceutical Recent Developments
- 4.3 CSPC Ouyi Pharmaceutical
- 4.3.1 CSPC Ouyi Pharmaceutical Company Information
- 4.3.2 CSPC Ouyi Pharmaceutical Business Overview
- 4.3.3 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- 4.3.5 CSPC Ouyi Pharmaceutical Recent Developments
- 4.4 Qilu Pharmaceutical
- 4.4.1 Qilu Pharmaceutical Company Information
- 4.4.2 Qilu Pharmaceutical Business Overview
- 4.4.3 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- 4.4.5 Qilu Pharmaceutical Recent Developments
- 4.5 Lepu Pharmaceutical
- 4.5.1 Lepu Pharmaceutical Company Information
- 4.5.2 Lepu Pharmaceutical Business Overview
- 4.5.3 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- 4.5.5 Lepu Pharmaceutical Recent Developments
- 4.6 Sino Therapeutics
- 4.6.1 Sino Therapeutics Company Information
- 4.6.2 Sino Therapeutics Business Overview
- 4.6.3 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- 4.6.5 Sino Therapeutics Recent Developments
- 4.7 Zydus
- 4.7.1 Zydus Company Information
- 4.7.2 Zydus Business Overview
- 4.7.3 Zydus Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- 4.7.5 Zydus Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Tofacitinib Citrate Extended-Release Tablets Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio
- 4.8.5 Pfizer Recent Developments
5 Global Tofacitinib Citrate Extended-Release Tablets Market Scenario by Region
- 5.1 Global Tofacitinib Citrate Extended-Release Tablets Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021-2032
- 5.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021-2026
- 5.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2027-2032
- 5.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2021-2032
- 5.3.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2021-2026
- 5.3.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2027-2032
- 5.4 North America Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
- 5.4.1 North America Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
- 5.4.3 North America Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
- 5.5.1 Europe Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
- 5.5.3 Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
- 5.6.1 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
- 5.7.1 South America Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
- 5.7.3 South America Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032)
- 6.1.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2032)
- 6.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2032)
- 6.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2032)
- 6.3 Global Tofacitinib Citrate Extended-Release Tablets Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032)
- 7.1.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2032)
- 7.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2032)
- 7.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2032)
- 7.3 Global Tofacitinib Citrate Extended-Release Tablets Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Tofacitinib Citrate Extended-Release Tablets Value Chain Analysis
- 8.1.1 Tofacitinib Citrate Extended-Release Tablets Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Tofacitinib Citrate Extended-Release Tablets Production Mode & Process
- 8.2 Tofacitinib Citrate Extended-Release Tablets Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Tofacitinib Citrate Extended-Release Tablets Distributors
- 8.2.3 Tofacitinib Citrate Extended-Release Tablets Customers
9 Global Tofacitinib Citrate Extended-Release Tablets Analyzing Market Dynamics
- 9.1 Tofacitinib Citrate Extended-Release Tablets Industry Trends
- 9.2 Tofacitinib Citrate Extended-Release Tablets Industry Drivers
- 9.3 Tofacitinib Citrate Extended-Release Tablets Industry Opportunities and Challenges
- 9.4 Tofacitinib Citrate Extended-Release Tablets Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst